Lumida
/SGHT
⌘K
Sight Sciences Inc

Sight Sciences Inc

SGHT
$8.14USD+1.69%+0.13 today

MARKET CAP

448.4M

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $8

52W RANGE

$3
$9

AI Summary

Stalk
Buy NowMedium

SGHT remains in a Stage 2 advancing phase, underpinned by an active Lockout Rally that has driven price above the 9 and 21 EMAs on rising volume. The medium-term bias is bullish, supported by a HH/HL sequence off the March low, while the long-term trend stays intact. Short-term execution is favorable now under the Lockout Rally override, so participation at shallow pullbacks into the EMAs aligns with continuation dynamics.

  • Q2 2026 revenue $23.4M (+20% YoY) with 91% gross margin
  • Interventional dry eye segment at $2.7M (+704% YoY) across 176 accounts
  • Earnings yield deeply negative and net loss $4.4M despite 63% improvement
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$49.0M$71.3M$81.1M$79.9M$77.4M
YoY %+45.7%+13.6%-1.5%-3.1%
P / Sales9.6x8.3x3.1x2.3x5.3x
EV / Sales5.3x6.4x1.9x1.5x4.8x
Gross Profit, Adj.$40.3M$59.0M$69.2M$68.3M$66.7M
YoY %+46.2%+17.3%-1.3%-2.4%
Margin %82.4%82.7%85.3%85.5%86.2%
EV / Gross Profit6.4x7.8x2.3x1.7x5.6x
EBITDA, Adj.$-50.8M$-83.2M$-56.7M$-49.8M$-36.6M
YoY %-63.7%+31.9%+12.1%+26.5%
Margin %-103.9%-116.7%-69.9%-62.4%-47.3%
EV / EBITDA-5.1x-5.5x-2.8x-2.4x-10.2x
EBIT$-51.5M$-84.0M$-57.3M$-50.5M$-37.1M
YoY %-63.1%+31.8%+11.8%+26.6%
Margin %-105.2%-117.7%-70.7%-63.3%-48.0%
EV / EBIT-5.0x-5.4x-2.7x-2.3x-10.1x
Net Income$-63.0M$-86.2M$-55.5M$-51.5M$-38.4M
YoY %-37.0%+35.6%+7.3%+25.4%
Net Margin-128.6%-120.9%-68.5%-64.5%-49.7%
EPS (GAAP)-$2.36-$1.80-$1.14-$1.03-$0.74
YoY %+23.7%+36.7%+9.6%+28.2%